Iain Kilty News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Iain kilty. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Iain Kilty Today - Breaking & Trending Today

Sitryx further strengthens leadership team with the appointment of Iain Kilty, Ph.D., as Chief Scientific Officer


Sitryx further strengthens leadership team with the appointment of Iain Kilty, Ph.D., as Chief Scientific Officer
April 15, 2021 02:00 ET
| Source:
Sitryx Therapeutics
Sitryx Therapeutics
LONDON, UNITED KINGDOM
Sitryx further strengthens leadership team with the appointment of Iain Kilty, Ph.D., as Chief Scientific Officer
Oxford, UK – 15 April 2021 – Sitryx (“the Company”), a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation, today announces the appointment of Iain Kilty, Ph.D., as its Chief Scientific Officer.
Iain will lead the development and execution of the Company’s research strategy and advancement of the Company’s pipeline of disease-modifying therapeutics in immuno-oncology and immuno-inflammation. ....

United Kingdom , David Daley , Melissa Gardiner , Mary Jane Elliott , Iain Kilty , Preclinical Sciences , Breast Cancer Research Laboratories , Immunology Research Unit At Pfizer , Jesus College , University Of Liverpool , United Kingdom Government Research Excellence Framework , University Of Cambridge , Sitryx The Company , Consilium Strategic Communications , Chief Scientific , Chief Executive Officer , Quench Bio , Chief Scientific Officer , Vice President Preclinical Sciences , Immunology Research Unit , Atlas Venture , United Kingdom Government , Research Excellence Framework , Jane Elliott , Sitryx Therapeutics , Sitryx Therapeutics ,

Quench Bio hit by 'successful failure,' winds down ops in Twitter thread as tech sold off at auction


(GH01/ iStock)
Quench Bio’s short journey has come to an end after the biotech startup found that its target was simply undruggable.
The Cambridge, Massachusetts-based biotech had focused on blocking the gasdermin D protein with oral inhibitors to treat inflammatory diseases and had attempted to seek out a potent, selective chemical series to progress by the first quarter of 2021.
It has not, however, managed to hit that goal, and, with credit to the company, it is not trying to spin out this failure, but says it now simply recommends “to wind down and return capital to investors.” It raised $50 million last year from the likes of RA Capital, AbbVie Ventures, Atlas Venture and Arix Bioscience, and was a 2020 Fierce 15 winner. ....

United States , United Kingdom , Mike Nolan , Arix Bioscience , Eli Lilly , Mark Tebbe , Samantha Truex , Paraza Pharma , Iain Kilty , Atlas Venture , Clinical Collaborative Research Organization , Bristol Myers Squibb , Quench Bio , Abbvie Ventures , Life Science Cares Boston , Padlock Therapeutics , Chief Technology Officer Mark Tebbe , Senior Director , Biology Mike Nolan , Big Pharma , Scientific Officer Iain Kilty , Fierce 15 , Failed Drug Program , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , மைக் நோலன் ,